This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 Apr 4.Search in Google Scholar
Grancharova G, Aleksandrova-Yankulovska S, Draganova M, et al. Trends in incidence of main types of cancer in Bulgarian women (2010-2021). Eur J Public Health. 2023 Oct 24;33(Suppl 2):ckad160.1556.Search in Google Scholar
Valerianova Z, Atanasov T. (editors). Cancer Incidence in Bulgaria, 2016 & 2017, Volume XXVI. Bulgarian National Cancer Registry. Sofia, Paradigma, 2020.Search in Google Scholar
Aiyappa-Maudsley R, McLoughlin LFV, Hughes TA. Semaphorins and Their Roles in Breast Cancer: Implications for Therapy Resistance. International Journal of Molecular Sciences. 2023; 24(17):13093.Search in Google Scholar
Mastrantonio R, You H, Tamagnone L. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer. Theranostics. 2021 Jan 15;11(7):3262-3277.Search in Google Scholar
Chen T, Li S, Wang L. Semaphorins in tumor microenvironment: Biological mechanisms and therapeutic progress. Int Immunopharmacol. 2024 May 10;132:112035.Search in Google Scholar
Gurrapu S, Pupo E, Franzolin G, et al. Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. Cell Death Differ. 2018 Jul;25(7):1259-1275.Search in Google Scholar
Yang J, Zeng Z, Qiao L, et al. Semaphorin 4C Promotes Macrophage Recruitment and Angiogenesis in Breast Cancer. Mol Cancer Res. 2019 Oct;17(10):2015-2028. doi: 10.1158/1541-7786.MCR-18-0933.Search in Google Scholar
Wei JC, Yang J, Liu D, et al. Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C. Clin Cancer Res. 2017 Jan 1;23(1):214-224.Search in Google Scholar
Li H, Li X, Xu S, et al. Semaphorin 4C accelerates disease progression and enables disease detection in breast cancer. Visualized Cancer Medicine. 2023; 4, 6.Search in Google Scholar
Wang Y, Qiao L, Yang J, et al. Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study. Cancer Commun (Lond). 2021 Dec;41(12):1373-1386.Search in Google Scholar
Neves Rebello Alves L, Dummer Meira D, Poppe Merigueti L, et al. Biomarkers in Breast Cancer: An Old Story with a New End. Genes (Basel). 2023 Jun 28;14(7):1364.Search in Google Scholar
Alto L T, Terman J R. Semaphorins and their Signaling Mechanisms. Methods in molecular biology (Clifton, N.J.), 2017, 1493, 1–25.Search in Google Scholar
Fard D, Tamagnone L. Semaphorins in health and disease. Cytokine Growth Factor Rev. 2021 Feb;57:55-63.Search in Google Scholar
Jiang J, Zhang F, Wan Y, et al. Semaphorins as Potential Immune Therapeutic Targets for Cancer. Front Oncol. 2022 Jan 27;12:793805.Search in Google Scholar
Franzolin G, Tamagnone L. Semaphorin Signaling in Cancer-Associated Inflammation. Int J Mol Sci. 2019 Jan 17;20(2):377.Search in Google Scholar
Ahammad I. A comprehensive review of tumor proliferative and suppressive role of semaphorins and therapeutic approaches. Biophys Rev. 2020 Oct;12(5):1233-1247.Search in Google Scholar
Bica C, Tirpe A, Nutu A, et al. Emerging roles and mechanisms of semaphorins activity in cancer. Life Sci. 2023 Apr 1;318:121499.Search in Google Scholar
Neufeld G, Mumblat Y, Smolkin T, et al. The role of the semaphorins in cancer. Cell Adh Migr. 2016 Nov;10(6):652-674.Search in Google Scholar
Yang Q, Wang Y, Lu X, et al. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells. Oncotarget. 2015 Feb 20;6(5):3268-79.Search in Google Scholar
Borges VF, Hu J, Young C, et al. Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. NPJ Breast Cancer. 2020 Oct 19;6:56.Search in Google Scholar
Jiang D, Chen X, Li X et al. Expression patterns and pathogenesis of Semaphorin class 4 subfamily proteins in solid tumors. Neoplasma. 2024 Feb;71(1):1-12.Search in Google Scholar
Paranthaman P, Veerappapillai S. Design of a potential Sema4A-based multi-epitope vaccine to combat triple-negative breast cancer: an immunoinformatic approach. Med Oncol. 2023 Feb 23;40(3):105.Search in Google Scholar
Shafique MR, Fisher TL, Evans EE, et al. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 Jul 1;27(13):3630-3640.Search in Google Scholar
Ye SM, Han M, Kan CY, et al. Expression and clinical significance of Sema4C in esophageal cancer, gastric cancer and rectal cancer. Zhonghua Yi Xue Za Zhi. 2012 Jul 24;92(28):1954-8.Search in Google Scholar
Wang Y, Liu J, Li J, et al. Serum semaphorin4C as an auxiliary diagnostic biomarker for breast cancer. Clin Transl Med. 2021 Aug;11(8):e480.Search in Google Scholar
Profil Orcid